GlassScriptPhysician profile
Diana Lopez
NPI 1871225755
$2,168.59
in general payments reported to CMS, 2019-2025
26 companies · $1,740 in 2025
The $1,740 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $93.89 · 2023: $193 · 2024: $142 · 2025: $1,740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,074.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $378.35 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Abbvie INC. | $306.42 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $186.07 | 2022-2025 | Farxiga, Lynparza, Enhertu |
| Janssen Biotech, INC. | $184.36 | 2025 | Rybrevant, Tecvayli, Darzalex |
| Novartis Pharmaceuticals Corporation | $104.41 | 2025 | |
| Lilly USA, LLC | $99.62 | 2022-2023 | Mounjaro, Trulicity, Jardiance |
| Daiichi Sankyo INC. | $96.51 | 2025 | Datroway, Enhertu |
| Glaxosmithkline, LLC. | $95.22 | 2025 | Jemperli, Zejula |
| Eisai INC. | $90.76 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.45 | 2024-2025 | Alunbrig, Iclusig |
| Genmab U.S., INC. | $64.70 | 2025 | Tivdak |
| Regeneron Healthcare Solutions, INC. | $62.86 | 2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $50.35 | 2025 | |
| Exelixis INC. | $46.56 | 2025 | Cabometyx |
| Incyte Corporation | $43.47 | 2025 | Monjuvi |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $42.26 | 2025 | Polivy, Tecentriq |
| Taiho Oncology, INC. | $38.98 | 2024-2025 | |
| Genzyme Corporation | $31.72 | 2024-2025 | |
| Tersera Therapeutics LLC | $29.81 | 2025 | Zoladex |
| Geron Corporation | $27.71 | 2025 | Rytelo |
| Medline Industries LP | $26.41 | 2024 | Medline |
| Legend Biotech USA INC. | $24.56 | 2025 | Carvykti |
| Novo Nordisk INC | $22.05 | 2023 | Rybelsus, Ozempic |
| Ipsen Biopharmaceuticals, INC | $20.95 | 2025 | Onivyde |
| Novocure INC. | $15.07 | 2025 | Optune Lua (Novottf-200t) |
| Xeris Pharmaceuticals, INC. | $13.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.